Your browser doesn't support javascript.
loading
UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy.
Diez, P; Hanna, G G; Aitken, K L; van As, N; Carver, A; Colaco, R J; Conibear, J; Dunne, E M; Eaton, D J; Franks, K N; Good, J S; Harrow, S; Hatfield, P; Hawkins, M A; Jain, S; McDonald, F; Patel, R; Rackley, T; Sanghera, P; Tree, A; Murray, L.
Afiliação
  • Diez P; Radiotherapy Physics, National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Cancer Centre, Northwood, UK.
  • Hanna GG; Belfast Health and Social Care Trust, Belfast, UK; Queen's University Belfast, Belfast, UK.
  • Aitken KL; Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; Institute of Cancer Research, London, UK.
  • van As N; Institute of Cancer Research, London, UK; Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Chelsea, London, UK.
  • Carver A; Department of Medical Physics, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK.
  • Colaco RJ; Department of Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UK.
  • Conibear J; Radiotherapy Department, Barts Cancer Centre, London, UK.
  • Dunne EM; Department of Clinical Oncology, Guys and St Thomas' NHS Foundation Trust, London, UK.
  • Eaton DJ; Radiotherapy Physics, National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Cancer Centre, Northwood, UK; Department of Medical Physics, Guys and St Thomas' NHS Foundation Trust, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London,
  • Franks KN; Department of Clinical Oncology, Leeds Cancer Centre, St James's University Hospitals, Leeds, UK.
  • Good JS; Department of Clinical Oncology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK.
  • Harrow S; Department of Clinical Oncology, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
  • Hatfield P; Department of Clinical Oncology, Leeds Cancer Centre, St James's University Hospitals, Leeds, UK.
  • Hawkins MA; Department of Medical Physics and Biomechanical Engineering, University College London, London, UK; Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Jain S; Belfast Health and Social Care Trust, Belfast, UK; Queen's University Belfast, Belfast, UK.
  • McDonald F; Institute of Cancer Research, London, UK; Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Chelsea, London, UK.
  • Patel R; Radiotherapy Physics, National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Cancer Centre, Northwood, UK.
  • Rackley T; Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK.
  • Sanghera P; Department of Clinical Oncology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK.
  • Tree A; Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; Institute of Cancer Research, London, UK.
  • Murray L; Department of Clinical Oncology, Leeds Cancer Centre, St James's University Hospitals, Leeds, UK; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK. Electronic address: L.J.Murray@leeds.ac.uk.
Clin Oncol (R Coll Radiol) ; 34(5): 288-300, 2022 05.
Article em En | MEDLINE | ID: mdl-35272913
The use of stereotactic ablative radiotherapy (SABR) in the UK has expanded over the past decade, in part as the result of several UK clinical trials and a recent NHS England Commissioning through Evaluation programme. A UK SABR Consortium consensus for normal tissue constraints for SABR was published in 2017, based on the existing literature at the time. The published literature regarding SABR has increased in volume over the past 5 years and multiple UK centres are currently working to develop new SABR services. A review and update of the previous consensus is therefore appropriate and timely. It is hoped that this document will provide a useful resource to facilitate safe and consistent SABR practice.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radiocirurgia / Carcinoma Hepatocelular / Neoplasias Hepáticas / Neoplasias Pulmonares Tipo de estudo: Guideline Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radiocirurgia / Carcinoma Hepatocelular / Neoplasias Hepáticas / Neoplasias Pulmonares Tipo de estudo: Guideline Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article